<?xml version="1.0" encoding="UTF-8"?>
<p>An important warning is given by Ewen Callaway in his article published in Nature (
 <xref rid="B43" ref-type="bibr">43</xref>), in which he asks for caution about the potential success of vaccines that arise from small animal or human studies. This might be the case of the Moderna-NIAID vaccine composed of lipid nano-particle encapsulated synthetic mRNA, which encodes the spike S protein and already underwent Phase I and II clinical trials in USA (
 <xref rid="B36" ref-type="bibr">36</xref>). Moderna company announced that Phase III trials are predicted to start in July 2020 and that studies in monkeys are underway in parallel. None of these mRNA based vaccine has ever been licensed before (
 <xref rid="B43" ref-type="bibr">43</xref>).
</p>
